OR WAIT null SECS
December 23, 2015.
Amgen (Thousand Oaks, CA) has acquired Catherex from Medigene (Munich, Germany) for an upfront payment of $10.5 million.
Medigene will receive about 40 percent of the payments from Amgen, while Catherex shareholders will receive the upfront payment plus milestone payments based on Amgen’s Imlygic, which was approved by FDA in October 2015 for the treatment of advanced, metastatic melanoma. Catherex, located in Philadelphia, PA, was spun off from Medigene in April 2010 with the development of a cancer-killing herpes simplex virus (oHSV).